Examining Drug Trend: Hepatitis C

Top 10 Classes - What is Driving Drug Trend

Drug price is driving trend. Overall utilization for the top 10 therapeutic classes in 2016 decreased, while prices increased. To better understand 2016 trend, we will be examining the top 10 therapeutic classes and their trend components. Previously, diabetes, inflammatory diseases and oncology. Today, we will examine Hepatitis C.

Hepatitis C
Although utilization and unit cost were both down for Hepatitis C in 2016, it still remains in the top five for PMPY spend with Harvoni leading the spend within the category.

Decreasing Utilization
Following the initial uptake of curative, blockbuster drugs, as anticipated, there was a decrease in overall utilization of Hepatitis C agents. By the end of 2016, the PMPM spend fell by nearly 50 percent of its peak within the two-year span.    

MedImpact anticipates that utilization will continue to drop as more patients are cured. However, the FDA may approve new treatments that will address patients who have failed previous treatments, which could affect cost and utilization in this category.

See our 2016 Annual Trend Report to learn more about trend drivers and forecasts for the top therapeutic classes. Make sure to check MedConnect for more in this series.

  • Email